{"id":"W4379521519","doi":"10.1136/annrheumdis-2023-eular.1722","title":"POS0232 POST-MARKETING SAFETY SURVEILLANCE OF TOFACITINIB OVER 9 YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada)","funders":"UCB Pharma; Medac; Eisai; Celgene; Biogen; Ortho Dermatologics; Gilead Sciences; Amgen; Pfizer; Eli Lilly and Company","keywords":"Tofacitinib; Medicine; Psoriatic arthritis; Rheumatoid arthritis; Adverse effect; Internal medicine; Safety profile; Ulcerative colitis; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006630353,0.00014516,0.0004906423,0.0000987758,0.00005863343,0.00000954376,0.0001814328,0.00008653454,0.0002313334],"category_scores_gemma":[0.001370831,0.0001002463,0.00011029,0.0003521804,0.0003532358,0.00005199855,0.000135677,0.000102143,0.000006664784],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000004752713,"about_ca_system_score_gemma":0.00003990817,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008072337,"about_ca_topic_score_gemma":0.00004757427,"domain_scores_codex":[0.9984108,0.0004866523,0.0005147429,0.0002022513,0.0001032121,0.0002823494],"domain_scores_gemma":[0.9984732,0.000841313,0.0002615406,0.0002810827,0.00010851,0.00003431648],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0009894106,0.0003081698,0.5850328,0.0002419915,0.0003168296,0.000002349104,0.0002547943,0.00001019682,0.000112627,0.0002548164,0.001524276,0.4109518],"study_design_scores_gemma":[0.001660895,0.0001340863,0.9954373,0.001651615,0.000009561127,0.000001708464,0.000124903,0.00001287293,0.0002570213,0.0003929486,0.0001886817,0.0001284118],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993014,0.005179424,0.000001770512,0.0004769055,0.0001267324,0.0002499738,0.0008772506,0.00002077977,0.00005314983],"genre_scores_gemma":[0.9940524,0.005662897,0.00004655216,0.0001299375,0.00000234337,0.000006692208,0.00004518198,0.00001268402,0.00004130761],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4108234,"threshold_uncertainty_score":0.4087925,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0114334463673926,"score_gpt":0.2519962390943637,"score_spread":0.2405627927269711,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}